These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 15958534)
1. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Clézardin P; Ebetino FH; Fournier PG Cancer Res; 2005 Jun; 65(12):4971-4. PubMed ID: 15958534 [TBL] [Abstract][Full Text] [Related]
2. The antitumor potential of bisphosphonates. Clézardin P Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of bisphosphonates. Green JR Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584 [TBL] [Abstract][Full Text] [Related]
4. Potential anticancer properties of bisphosphonates. Neville-Webbe HL; Gnant M; Coleman RE Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373 [TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates: preclinical review. Green JR Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in preclinical bone oncology. Clézardin P; Benzaïd I; Croucher PI Bone; 2011 Jul; 49(1):66-70. PubMed ID: 21145441 [TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Clézardin P Bone; 2011 Jan; 48(1):71-9. PubMed ID: 20655399 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumor potential of bisphosphonates. Green JR Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of bisphosphonates: promising preclinical evidence. Guise TA Cancer Treat Rev; 2008; 34 Suppl 1():S19-24. PubMed ID: 18486348 [TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacology of zoledronic acid. Green JR Semin Oncol; 2002 Dec; 29(6 Suppl 21):3-11. PubMed ID: 12584689 [TBL] [Abstract][Full Text] [Related]
11. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139 [TBL] [Abstract][Full Text] [Related]
12. The potential role of bisphosphonates in prostate cancer. Oades GM; Coxon J; Colston KW Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696 [TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Rogers MJ; Xiong X; Brown RJ; Watts DJ; Russell RG; Bayless AV; Ebetino FH Mol Pharmacol; 1995 Feb; 47(2):398-402. PubMed ID: 7870050 [TBL] [Abstract][Full Text] [Related]
15. Clinical value of bisphosphonates in cancer therapy. Lüftner D; Henschke P; Possinger K Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770 [TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of action of bisphosphonates: current status. Roelofs AJ; Thompson K; Gordon S; Rogers MJ Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705 [TBL] [Abstract][Full Text] [Related]
17. [Molecular basis of bone metastasis formation and its targeted therapy]. Tímár J Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates in oncology: rising stars or fallen heroes. Van den Wyngaert T; Huizing MT; Fossion E; Vermorken JB Oncologist; 2009 Feb; 14(2):181-91. PubMed ID: 19179412 [TBL] [Abstract][Full Text] [Related]
19. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Green JR Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells. Merrell MA; Wakchoure S; Ilvesaro JM; Zinn K; Gehrs B; Lehenkari PP; Harris KW; Selander KS Eur J Pharmacol; 2007 Mar; 559(1):21-31. PubMed ID: 17214981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]